Receptor News and Research

RSS

Naurex's GLYX-13 receives FDA Fast Track designation

Naurex Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation to the investigation of GLYX-13, the company's rapid-acting antidepressant in Phase 2 clinical development, as adjunctive therapy in major depressive disorder.

4 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Five women scientists to receive ‘L’Oréal-UNESCO For Women in Science Awards'

On March 19th the L'Oréal Foundation and UNESCO will present the L'Oréal-UNESCO For Women in Science awards to five outstanding women scientists.

3 Mar 2014

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment.

3 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

3 Mar 2014

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.

3 Mar 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

Vaccine targeting tumors could initiate immune response to fight cancer

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

28 Feb 2014

Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists from The University of Manchester - part of the Manchester Cancer Research Centre (MCRC) - have discovered a new protein that is involved in cancer and inflammation in lung tissue.

From The University of Manchester 28 Feb 2014

UH scientists working to develop next generation of prostate cancer therapies

A University of Houston scientist and his team are working to develop the next generation of prostate cancer therapies, which are targeted at metabolism.

27 Feb 2014

H4 receptor activation plays part in NSCLC progression

Histamine H4 receptor activation decreases epithelial-to-mesenchymal transmission in non-small-cell lung cancer, Chinese research shows.

27 Feb 2014

New way to potentially block chronic pain affecting osteoarthritis sufferers

Researchers from the Arthritis Research UK Pain Centre at The University of Nottingham have discovered a new way to potentially block the chronic and often debilitating pain affecting osteoarthritis sufferers.

26 Feb 2014

Johns Hopkins researchers use tiny particles to train immune systems of mice to fight melanoma

Using tiny particles designed to target cancer-fighting immune cells, Johns Hopkins researchers have trained the immune systems of mice to fight melanoma, a deadly skin cancer. The experiments, described tk on the website of ACS Nano, represent a significant step toward using nanoparticles and magnetism to treat a variety of conditions, the researchers say.

26 Feb 2014

Researcher identifies ''conductor'' in development of muscle tissue

A team led by Jean-Fran-ois C-t-, researcher at the IRCM, identified a ''conductor'' in the development of muscle tissue. The discovery, published online yesterday by the scientific journal Proceedings of the National Academy of Sciences (PNAS), could have an important impact on the treatment of muscular diseases such as myopathies and muscular dystrophies.

26 Feb 2014

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests.

25 Feb 2014

Researchers produce extremely accurate and detailed images of "toxic injections"

Bacteria have developed many different ways of smuggling their toxic cargo into cells. Tripartite Tc toxin complexes, which are used by bacteria like the plague pathogen Yersinia pestis and the insect pathogen Photorhabdus luminescens, are particularly unusual.

25 Feb 2014

Origin of deadly human malaria parasite linked to primates in Africa, not Asia

An international team of scientists has traced the origin of Plasmodium vivax, the second-worst malaria parasite of humans, to Africa, according to a study published this week in Nature Communications.

25 Feb 2014

New system delivers anti-inflammatory drugs to immune cells gone out of control

Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts. Their findings were published online Feb. 23 in Nature Nanotechnology.

24 Feb 2014